4.37 USD
↘ 0.01 (0.32%)LIVE (AS OF 03:24 PM EDT)
Verrica Pharmaceuticals Inc. Common Stock
VRCANASDAQ • USD
Market: OPEN
Verrica Pharmaceuticals Inc. Common Stock (VRCA) trades at $4.37 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place VRCA at a fair price relative to peers.
Technical & fundamental data as of Oct 2, 2026.
Open?$4.34
High?$4.51
Low?$4.27
Prev. Close?$4.38
Volume?22.9K
Avg. Volume?78.5K
VWAP?$4.37
Rel. Volume?0.29x
Bid / Ask
Bid?$4.33 × 100
Ask?$4.92 × 100
Spread?$0.59
Midpoint?$4.63
Valuation & Ratios
Market Cap?75.2M
Shares Out?17.2M
Float?7.8M
Float %?45.7%
P/E Ratio?N/A
P/B Ratio?17.47
EPS?-$1.82
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Address
44 WEST GAY STREET
WEST CHESTER, PA
Phone: 484-453-3300
WEST CHESTER, PA
Phone: 484-453-3300
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?0
Momentum?8
Short Sent.?63
Piotroski F-Score?1/9Weak
Altman Z-Score?-13.77Distress
Confidence?53%Low
Short InterestModerate
Short % of Float?2.58%Low
Short Interest?202.8K
Days to Cover?4.2
Free Float7.8M
Avg Daily Volume48.5K
Settlement Date2026-09-15
Financial Health
Current Ratio?1.06Adequate
Quick Ratio?0.97Weak
Cash Ratio?0.36Low
Debt/Equity?0.32Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?17.47HIGH▾
Peers100
S&P9
P/S?2.48CHEAP▾
Peers100
S&P58
P/FCF?N/A▾
EV/EBITDA?-2.5CHEAP▾
S&P97
EV/Sales?2.16CHEAP▾
Peers100
S&P72
Returns & Efficiency
ROE?-724.0%WEAK▾
S&P3
ROA?-86.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-13347000
Enterprise Value?$65.4M
Fundamentals ratios updated end of day